Abstract
Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Current Enzyme Inhibition
Title: Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius
Volume: 7 Issue: 2
Author(s): Kalyan K. Sethi, Padilam Suresh and Sumanta Mondal
Affiliation:
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Abstract: Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Export Options
About this article
Cite this article as:
K. Sethi Kalyan, Suresh Padilam and Mondal Sumanta, Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius, Current Enzyme Inhibition 2011; 7 (2) . https://dx.doi.org/10.2174/157340811796575272
DOI https://dx.doi.org/10.2174/157340811796575272 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ATP-Sensitive Potassium Channels
Current Pharmaceutical Design Distinct Forms of Spinal Cysticercosis: A Vietnamese Case Series
Current Medical Imaging Synthesis and Preliminary Biochemical Evaluation of Novel Derivatives of PCP
Letters in Drug Design & Discovery Editorial [Hot Topic: New Mechanisms of Neuronal Injury and Neuroprotection (Guest Editor: Weihai Ying)]
Current Drug Targets Editorial: Look for Changes in 2016
Current Molecular Medicine Perspective on mTOR-dependent Protection in Status Epilepticus
Current Neuropharmacology Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Nutritional and Pharmacological Management of Childhood Epilepsy: Ketogenic Diets and Common AEDs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications
Current Neuropharmacology Can FreeSurfer Compete with Manual Volumetric Measurements in Alzheimer’s Disease?
Current Alzheimer Research Nerolidol and its Pharmacological Application in Treating Neurodegenerative Diseases: A Review
Recent Patents on Biotechnology Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles
Current Drug Delivery Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms
CNS & Neurological Disorders - Drug Targets Pediatrics for Disability: A Comprehensive Approach to Children with Syndromic Psychomotor Delay
Current Pediatric Reviews Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets
Current Protein & Peptide Science Phytol a Natural Diterpenoid with Pharmacological Applications on Central Nervous System: A Review
Recent Patents on Biotechnology Deep Brain Stimulation for Alzheimer’s Disease
Current Alzheimer Research